Prognostic Factors in a Cohort of Dacarbazine Treated Patients for Metastatic Melanoma

被引：0
|
作者：
Bexiga, J. Godinho [1 ]
Carneiro, F. [1 ]
Sousa, N. [1 ]
Ferreira, P. [1 ]
Raimundo, A. [1 ]
机构：
[1] IPO Porto, Serv Oncol Med, Oporto, Portugal
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72530-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S658 / S658
页数：1
相关论文
共 50 条
  • [21] Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy
    Keilholz, U
    Scheibenbogen, C
    Sommer, M
    Pritsch, M
    Geuke, AM
    MELANOMA RESEARCH, 1996, 6 (02) : 173 - 178
  • [22] A phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma
    Munzone, E.
    Testori, A.
    Minchella, I.
    Mosconi, M.
    Passoni, C.
    Verri, E.
    Rocca, M. Cossu
    Lambiase, A.
    Goldhirsch, A.
    Nole, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] BLEOMYCIN, CARMUSTINE, VINCRISTINE, AND DACARBAZINE IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA
    COHEN, SM
    OHNUMA, T
    CHEUNG, T
    HOLLAND, JF
    CANCER TREATMENT REPORTS, 1983, 67 (10): : 947 - 948
  • [24] Prognostic factors for response to chemoimmunotherapy in metastatic melanoma
    Ortega, Eugenia
    Polo, Eduardo
    Lara, Ricardo
    Lastra, Rodrigo
    Lambea, Julio
    Andres, Raquel
    Ignacio Mayordomo, J.
    Saenz, Alberto
    Isla, Dolores
    Tres, Alejandro
    ANNALS OF ONCOLOGY, 2004, 15 : 205 - 205
  • [25] Favorable prognostic factors in recurrent and metastatic melanoma
    Buzzell, RA
    Zitelli, JA
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (05) : 798 - 803
  • [26] Clinical Prognostic Factors in metastatic Choroidal Melanoma
    Koch, E.
    Petzold, A.
    Wessely, A.
    Dippel, E.
    Erdmann, M.
    Heinzerling, L.
    Hohberger, B.
    Knorr, H.
    Leiter-Stoppke, U.
    Meier, F.
    Mohr, P.
    Rahimi, F.
    Schell, B.
    Schlaak, M.
    Terhey-Den, P.
    Schuler-Thurner, B.
    Ugurel, S.
    Utikal, J. S.
    Vera, J.
    Weichenthal, M.
    Ziller, F.
    Berking, C.
    Heppt, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 82 - 83
  • [27] Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib±cobimetinib: a pooled analysis of four clinical trials
    Ascierto, Paolo A.
    Ribas, Antoni
    Larkin, James
    McArthur, Grant A.
    Lewis, Karl D.
    Hauschild, Axel
    Flaherty, Keith T.
    McKenna, Edward
    Zhu, Qian
    Mun, Yong
    Dreno, Brigitte
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [28] Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
    Paolo A. Ascierto
    Antoni Ribas
    James Larkin
    Grant A. McArthur
    Karl D. Lewis
    Axel Hauschild
    Keith T. Flaherty
    Edward McKenna
    Qian Zhu
    Yong Mun
    Brigitte Dréno
    Journal of Translational Medicine, 18
  • [29] Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab
    Lucia Brilli
    Riccardo Danielli
    Cristina Ciuoli
    Luana Calabrò
    Anna Maria Di Giacomo
    Alfonso Cerase
    Patrizia Paffetti
    Fausta Sestini
    Brunetta Porcelli
    Michele Maio
    Furio Pacini
    Endocrine, 2017, 58 : 535 - 541
  • [30] Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab
    Brilli, Lucia
    Danielli, Riccardo
    Ciuoli, Cristina
    Calabro, Luana
    Di Giacomo, Anna Maria
    Cerase, Alfonso
    Paffetti, Patrizia
    Sestini, Fausta
    Porcelli, Brunetta
    Maio, Michele
    Pacini, Furio
    ENDOCRINE, 2017, 58 (03) : 535 - 541
12345